Hemispherx' Ampligen NDA delayed up to two weeks

25 May 2009

The US drug developer Hemispherx Biopharma has been told that the Food and Drug administration may require up to two additional weeks to take  action beyond the May 25 action date on the New Drug Application for  Ampligen (Poly I Poly C12U), its selective TLR3 modulator, for the  management of chronic fatigue syndrome.

A reason for the possible delay was attributed by the Agency to certain  staff scheduling changes which might delay the report. The firm stressed  that the FDA did not request any additional information on the NDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight